GSA Capital Partners’s Cytek Biosciences CTKB Stock Holding History

GSA Capital Partners’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$742K	Buy	167,593 +58,477	+54%	+$250K	0.05%	717
2026 Q1	$477K	Buy	+109,116	New	+$515K	0.03%	950
2025 Q4	–	Sell	-109,098	Closed	-$379K	–	1734
2025 Q3	$379K	Buy	109,098 +73,932	+210%	+$278K	0.03%	1049
2025 Q2	$120K	Sell	35,166 -43,896	-56%	-$146K	0.01%	1596
2025 Q1	$317K	Buy	+79,062	New	+$410K	0.03%	1111
2024 Q4	–	Sell	-37,884	Closed	-$210K	–	1676
2024 Q3	$210K	Buy	37,884 +23,237	+159%	+$132K	0.02%	1398
2024 Q2	$82K	Buy	+14,647	New	+$88K	0.01%	1542
2022 Q3	–	Sell	-73,743	Closed	-$791K	–	1576
2022 Q2	$791K	Buy	+73,743	New	+$734K	0.12%	236

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GSA Capital Partners's CTKB Position: Q2 2026 in Review

GSA Capital Partners increased its Cytek Biosciences (CTKB) stake by 54% in Q2 2026, buying an estimated $250K and bringing the position to 167,593 shares worth $742K. The position accounts for 0.05% of the portfolio, ranked #717.

GSA Capital Partners first reported a position in CTKB in Q2 2022 and has held it in 8 quarters since. The position peaked at $791K in Q2 2022. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

GSA Capital Partners held 167,593 shares of Cytek Biosciences worth $742K as of Q2 2026.
GSA Capital Partners bought 58,477 Cytek Biosciences shares in Q2 2026, an estimated $250K.
Cytek Biosciences made up 0.05% of GSA Capital Partners's portfolio in Q2 2026, its #717 holding.
GSA Capital Partners first reported a position in Cytek Biosciences in Q2 2022 and has held it in 8 quarters since.
GSA Capital Partners's Cytek Biosciences position peaked at $791K in Q2 2022.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.